Catalyst Biosciences, Inc. (CBIO)
After hours:
| Previous close | 1.2000 |
| Open | 1.2000 |
| Bid | 1.1400 x 3200 |
| Ask | 1.2100 x 800 |
| Day's range | 1.1301 - 1.2100 |
| 52-week range | 1.1301 - 7.5500 |
| Volume | |
| Avg. volume | 594,601 |
| Market cap | 36.121M |
| Beta (5Y monthly) | 1.77 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.0550 |
| Earnings date | 12 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 20 Aug 2015 |
| 1y target est | 11.67 |
- GlobeNewswire
Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29-December 2, 2021. The fireside chat will be available on-demand for registered attendees via the Piper Sandler conference site beginning Monday, November 22, 2021 at 10:00 am ET until the end of the conference
- GlobeNewswire
Catalyst Biosciences Announces Change in Corporate Strategy
Reports Third Quarter 2021 Operating & Financial ResultsCompany to discontinue MarzAA development; focus on developing its complement portfolio Management to host a call today at 8:30 am ET SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced a strategic decision to halt the clinical development of MarzAA, report data to date, and seek a buyer for its hemophilia assets. Catalyst plans to focus its resources on its complement the
